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Phase 3 study examining adjunctive armodafinil for the treatment of a major 
depressive episode associated with bipolar I disorder (NCT01072929). METHODS: 
To assess the safety and efficacy of adjunctive armodafinil 150 mg/day in a 
heterogeneous sample of patients, this 8-week, double-blind, placebo-controlled, 
multicenter study evaluated adult patients with bipolar I disorder who were 
currently experiencing a major depressive episode while taking 1-2 maintenance 
therapies (mood stabilizers and/or second-generation antipsychotics). RESULTS: 
The study was conducted at 70 centers in 10 countries from January 2010 to 
March 2012. Of 786 patients screened, 433 were randomized. Baseline disease 
severity as assessed by mean (SD) IDS-C30 total scores was characteristic of 
moderate depression (43.6 [6.93] and 43.2 [7.76] for the placebo and 150 mg 
groups, respectively). The most common concomitant treatments were 
valproate, lithium, and lamotrigine. Patients in the placebo and armodafinil 150 
mg groups experienced their first depressive episode 13.8 (SD 10.24) and 14.5 (SD 
11.73) years prior to screening, respectively. The number of distinct regimens of 
adjunctive treatments will also be reported. CONCLUSIONS: Because the design 
allowed a wider range of adjunctive maintenance therapies, subjects enrolled in 
this study may be more representative of patients in clinical practice. The 
diversity of therapeutic regimens encountered in this study may improve 
external validity/generalizability without sacrificing assay sensitivity, although a 
large sample size was necessary. Further studies are needed to explore how 
research on bipolar depression treatments can improve external validity by 
employing more inclusive designs without sacrificing assay sensitivity.  
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INVESTIGATOR-INITIATED APPROACH TO ADDRESS AN OPTIMIZATION 
PROBLEM IN DESIGNING COST-EFFICIENT STUDIES  
Huynh L1, Clark M2, Frick KD3 
1Analysis Group, Boston, MA, USA, 2Brown University, Providence, RI, USA, 3Johns Hopkins 
Bloomberg School of Public Health, Baltimore, MD, USA  
OBJECTIVES: To improve research productivity in an economic environment 
with limited resources, researchers may need to consider investigator-initiated 
approaches to design cost-efficient studies. A cost function was developed to 
guide decisions about trade-offs to be made in clinical trial design with the 
objective of minimizing cost while achieving a given level of power to detect 
differences in patient-reported outcomes. METHODS: The design and conduct of 
a clinical study was treated as a constrained optimization problem. A cost 
function was developed, a Lagrangian function was constructed, and first-order 
partial derivatives were taken with respect to each choice variable (e.g., number 
of recruitment sites, number of follow-up visits, and study duration). 
Comparative statics analysis was used to examine the changes in the choice 
variables as a result of changes in the exogenous variables. RESULTS: A 
necessary condition to minimize cost while achieving a given power is the 
equivalence of the ratios of the marginal cost associated with increasing each 
choice variable and the marginal change in power associated with each choice 
variable; in other words the same cost per unit of output created by each input at 
the margin. For second-order condition, we made the reasonable assumption 
that increasing the number of participants recruited leads to a decrease in the 
marginal rate of change in the Type II error which holds. Comparative statics 
analysis showed that the increase or decrease in the rate of recruitment, 
expected percent loss to follow-up, and the cost of interventions lead to different 
trade-offs between the marginal cost of conducting the clinical trial and the 
marginal change in the probability of committing a Type II error. CONCLUSIONS: 
In light of funding challenges, researchers could consider the trade-offs required 
to achieve a cost-efficient study for a given level of power using methods from 
economics and optimization.  
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MULTI-NATIONAL RETROSPECTIVE CHART REVIEW STUDIES: LESSONS 
LEARNED FROM APPLICATION OF METHODOLOGY TO INTERNATIONAL 
EVALUATIONS OF BURDEN OF ILLNESS AND DRUG UTILIZATION AND  
SAFETY  
Payne KA1, Stein D1, Stemhagen A2 
1United BioSource Corporation, Dorval, QC, Canada, 2United BioSource Corporation, Blue Bell, PA, 
USA  
OBJECTIVES: In the absence of suitable health care databases, chart review 
studies can result in tailored datasets suitable for evaluations of burden of 
illness, unmet need and drug utilization and safety. This methodology, however, 
is associated with significant design and operational challenges. METHODS: 
Design and operational parameters of ten recent chart review studies of 
treatment patterns, resource utilization and costs of care, clinical outcomes 
and/or drug utilization and safety conducted in Canada, the United States, and 
western Europe have been summarized. Opportunities, challenges and lessons 
learned have been delineated in detail. RESULTS: Four of these studies were 
categorized as post authorization safety studies, and all but one of these studies 
was mandated by the FDA or EMA. Six of the 10 studies were in oncology, and 
evaluated outcomes in patients who had failed at least one line of 
chemotherapy. Sample size varied from 20 patients to greater than 2000, and the 
number of countries and sites varied from 1-6 and 4 to 375 respectively. Across 
studies, key challenges included delineation of eligibility and study periods that 
permit evaluations of recent care patterns yet allow for sufficient follow-up time; 
design and local implementation of case ascertainment and sampling frame 
methodologies; and safety reporting in the context of retrospective source data. 
Drug utilization studies evaluating inappropriate or off-label use required careful 
attention to protocol language to minimize response bias, as well as a carefully 
executed operational plan for the identification of prescribers and the collection 
of data from prescribers over time. CONCLUSIONS: Though challenging to 
implement, retrospective chart reviews are frequently necessary to address 
research questions spanning burden and costs of care to drug utilization and 
safety. A series of national and multi-national chart review case studies with 
diverse research objectives highlight common design and operational challenges 
that can be anticipated and overcome.  
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TIME AND MOTION STUDY DESIGN: HANDLING VARIABILITY AND 
CONFOUNDING OF RESULTS  
Yeomans K1, Payne KA1, Pan YI1, De Cock E2 
1United BioSource Corporation, Dorval, QC, Canada, 2United BioSource Corporation, Barcelona, 
Spain  
Time and Motion (T&M) studies quantify time-related outcomes. Any given 
intervention process can be broken down into a set of pre-defined tasks for 
repeated observations, allowing estimation of the mean task durations in 
support of health economic analyses. While aiming to achieve robust estimates, 
variability in time measurements remains a main methodological challenge. 
OBJECTIVES: To discuss the importance of handling variability and confounding 
in T&M studies. METHODS: Investigation of the impact of variability on process 
duration begins with the analysis of process flow predictors and particularly the 
identification of potential confounders of process duration. Process-related 
variability can result from differences between countries or centers  
(e.g., geography, institution type) or within centers (e.g., patient characteristics, 
process specifics). Additional variability in time measurements can be due to 
insufficient delineation of tasks and inter-rater differences. RESULTS: Once 
potential sources of variability are identified, it must be decided whether  
a variable is to be minimized or accounted for in the study design relating back 
to the health economics objective of the T&M study. For instance, clear 
delineation of processes to be observed and thorough training help limit  
inter-rater variability. On the other hand, limiting data collection to a 
homogenous sample of centers and patients (i.e., specific patient and process 
characteristics), while minimizing variability in study setting and population, 
can compromise generalizability of the results. In situations where a medical 
intervention can be used to treat a broad range of patient populations with 
distinct clinical characteristics, limiting data collection to a certain subgroup 
means generating results applicable to these patients only. CONCLUSIONS: 
Variability can be controlled through thoughtful study design. However, 
significant confounders should be identified and accounted for to produce valid 
process time estimation. Proper handling of variability in time measurement will 
improve precision of the duration estimates in support of health economic 
analyses.  
 
RESEARCH ON METHODS – Conceptual Papers 
 
PRM218  
THE CHALLENGE OF EVIDENCE SYNTHESIS WITH SPARSE OR RARE EVENTS: 
HOW BAYES CAN HELP?  
Amzal B1, Nikodem M2 
1LA-SER Analytica, London, UK, 2CASPolska, Myslenice, Poland  
BACKGROUND: With the emergence of systematic reviews for evidence-based 
evaluations in health care, the quantitative methods to synthesize evidence have 
been increasingly developed and used to support decision making Particularly in 
the context of HTA evaluations where both post-marketing and pre-marketing 
data may be considered, the evidence to be synthesized can be sparse or related 
to rare outcomes such as risk outcomes. The Bayesian option has increasingly 
appeared as an unrivalled option for such challenging evidence synthesis cases. 
OBJECTIVES: This work aims at highlighting the strengths and limitations of 
Bayesian meta-analysis and mixed treatment comparisons and at providing 
guidance to doers and users of such evidence syntheses in the context of health 
technology assessment with rare or sparse health outcomes in the real-world 
setting. METHODS: Through a list of case studies in risk or benefit/risk studies 
and simulation-based comparisons, the state-of-the-art Bayesian meta-analytic 
approaches are reviewed, adapted to the context of rare events and evaluated for 
their robustness. Under-reporting of risk outcomes in post-marketing studies is 
accounted for in the Bayesian models and sensitivity to the choice of priors is 
analyzed. RESULTS: Provided thorough validation procedures and careful model 
and prior calibration, the Bayesian framework offers an unrivalled framework for 
evidence synthesis of scarce data, for both direct and indirect comparisons, with 
fair and robust quantification of uncertainty. CONCLUSION: Guidance can be 
derived based on the nature and quantity of data which do impact the methods 
reliability, in order to help practitioners and decision makers in using Bayesian 
meta-analysis and models for scarce data in various country and decision 
settings.  
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THE VALUE OF A GOOD DECISION: ASSESSING THE ECONOMIC BENEFITS OF 
DECISION AIDS  
Butt T1, Findl O2, Orr S1, Rubin G1 
1University College London, London, UK, 2Hanusch Hospital, Vienna, Austria  
Decision aids are increasingly used to support doctors and patients in shared 
health care decision making, yet methods to measure their benefits for economic 
evaluation have received limited attention. Significant non-health benefits such 
as improved patient knowledge, experience and satisfaction may accrue through 
the use of decision aids. These cannot be assessed within the dominant health 
economic framework of cost utility analysis. The objective of this paper is to 
propose a new opportunity cost-based method suitable for assessing the benefits 
of decision aids relative to other interventions in a resource-constrained health 
care system. A literature review to identify how decision aids have been 
evaluated found that economic evaluations are limited. Non-health benefits 
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have been measured with knowledge and satisfaction questionnaires, but have 
not been assessed within a choice-based methodology. The key function of a 
decision aid is to provide information for a patient to make an informed decision 
and the displaced activity within the health care system (the opportunity cost) 
would be physician consultation time. We propose a stated preference 
consultation time trade-off (CTTO) in which a proportion of a hypothetical 10-
minute physician consultation is traded for use of the decision aid by a patient 
with prior experience of the aid. Conceptually, a patient is trading a substitute 
source of health care information to maximise their utility of the consultation 
experience. The CTTO may be reported in consultation minutes or converted to a 
monetary value using the local cost of physician time. These values can be used, 
alongside the cost of the decision aid, for economic evaluation. The CTTO is 
currently being evaluated within a clinical trial of a cataract decision support 
tool.  
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DIRECT-TO-PATIENT STUDY DESIGNS FOR PHARMACOVIGILANCE  
de Moor C1, Michel J2, Wiederkehr S2, Jones M1, Fournie X2 
1REGISTRAT-MAPI, Lexington, KY, USA, 2REGISTRAT-MAPI, Lyon, France  
Post-marketing non-interventional safety studies typically enroll patients at sites 
where patients receive care. During patient follow-up the occurrence of safety 
events of interest is recorded by site personnel based on information obtained 
from the patient during standard-of-care visits. Although this is the traditional 
approach for assessing the occurrence of safety events in the post marketing 
setting, it has several practical shortcomings, including; high cost associated 
with site start up, management, and data collection; infrequent or irregular 
standard-of-care visits; patients switching health care providers; transient 
nature of some safety events; treatment at non-study sites, and the lack of care-
seeking for the safety events. A design alternative that overcomes several  
of these short comings includes direct-to-patient contact and follow-up. In this 
approach, enrolled patients are regularly contacted via phone during follow-up 
and interviewed regarding the occurrence of safety events or potential signs  
and symptoms associated with the safety events. If either is reported by the 
patient, trained personnel follow up with the patient’s treating physician for 
further evaluation through phone interview and/or written confirmation of the 
safety event. We will present three examples of studies that make use of this 
direct-to-patient approach to capturing safety data. These studies comprise large 
multi-national and national studies with sample sizes ranging between 2000 to 
over 10,000 patients. In one study, the safety events include thromboembolotic 
and bleeding events in patients discharged from hospitalization for acute 
coronary syndrome. In two others, safety events comprise anaphylaxis, 
encephalitis, Bell’s palsy, neuritis, etc. associated with influenza vaccines. For 
each study, we will present specific design characteristics; procedures for patient 
contact, follow-up, and interviews; and procedures for confirming the 
occurrence of safety events. Strengths and weaknesses of the direct-to-patient 
approach will be discussed and recommendations regarding appropriate 
indications and safety events best suited to this novel methodology will be 
presented.  
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MPR AND PDC: IMPLICATIONS FOR INTERPRETATION OF ADHERENCE 
RESEARCH RESULTS  
Clancy ZA 
Jefferson School of Population Health, Philadelphia, PA, USA  
OBJECTIVES: To compare and contrast the Medication Possession Ratio (MPR) 
and Proportion of Days Covered (PDC) measures of adherence and explore  
the implications of measure choice and specific definition on study results. 
METHODS: Two adherence measures, MPR and PDC, were selected for 
comparison because of their prominence in the claims database research 
literature. To highlight the effect of measure selection, examples demonstrating 
contrasting results for MPR and PDC are presented. Furthermore, the impact  
of numerator and denominator specification within each of those measures  
is examined and illustrated with examples. Implications for assessing  
and interpreting published research studies are presented. RESULTS: Although 
MPR and PDC have been operationally defined in similar ways in the literature, 
there are differences that could yield distinct results. The basic structure of these 
measures is a ratio with a proxy for the number of compliant days in  
the numerator and the number of days in a measurement period in  
the denominator. MPR is based on the sum of dispensed ‘days supply’ over  
a period, whereas PDC is based on evaluation of available supply for each 
individual day in the period. A demonstration is provided on how research 
design choices of MPR or PDC and specification of numerator and denominator 
can result in different findings for a given research question. CONCLUSIONS: 
Despite the similar structure of MPR and PDC metrics, study design choices  
can affect study results considerably. Selection of an adherence measure must 
be tailored to the therapeutic area, relevant medications, and research 
objectives. Researchers should be transparent in the specification of measures 
used and readers need to understand the implication of these research design 
decisions.  
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EVALUATING THE COST OF OPIOID DEPENDENCE TREATMENT MODELS IN 
EUROPE  
Taylor M, Lewis L 
York Health Economics Consortium, York, UK  
Opioid dependence incurs significant harm and associated economic costs 
worldwide. Whilst investment in medication-assisted treatment interventions 
cost-effectively reduces these harms, models of care for opioid dependence  
vary substantially between countries. Quantification of opioid-dependence 
treatment costs could help to optimise health policy decision-making regarding 
treatment provision. A health economic (HE) model was developed to calculate 
the costs associated with different treatment models of care in use across Europe 
allowing for comparison of different treatment systems. Total costs incurred, on 
a per-patient and national level, were calculated. A literature review was 
undertaken in order to find all relevant evidence on the treatment of opioid 
dependence. The HE model assesses direct costs (including medications, 
supervision and dispensing, staff costs, testing costs, other health care costs and 
miscellaneous costs) associated with the model of treatment in place in each 
country, according to national guidelines, and allows for comparison of the costs 
associated with different medication options. Local cost data were sourced by 
health economics groups in each of the relevant countries, and were drawn from 
publicly available databases and published literature where possible. Expert 
opinion was used to fill in any remaining data gaps. Seven countries were 
included in the analysis with the initial focus being Belgium, France, Germany, 
Italy, Portugal, Spain and UK. The primary output of the HE model, which will be 
presented, is the total per-patient cost of providing treatment for opioid 
dependence in each country. The HE model also provides the total cost of each 
treatment model in each country. Outputs are being validated against publicly 
available statistics on the total number of patients treated and the total cost to 
treat them, in each country. This HE model provides a tool to support 
discussions on and implementation of cost-effective models of care for opioid 
dependence around Europe.  
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IMPLEMENTATION OF PATIENT-REPORTED OUTCOMES ASSESSMENT IN A 
POST MARKETING SAFETY SURVEILLANCE: PARALLELS IN JAPAN AND  
GLOBAL PLANNING  
Adachi K1, Migita H2, Yamanaka S2, Wang ECY1, Rossi B2 
1Bayer Yakuhin, Ltd., Tokyo, Japan, 2Bayer Yakuhin, Ltd., Osaka, Japan  
The importance of incorporating patient-reported outcomes (PRO) assessment 
into the practice of medicine is well recognized. Measurement of PRO in real-
world clinical practice, however, is not commonly performed because of limited 
time spent with patients due to the busy schedules of clinicians, whose primary 
focus is to achieve a symptomatic cure. A post marketing safety surveillance 
(PMS) is one of a few opportunities to obtain non-interventional, prospective, 
real-world data about PRO, since PMS is a must due to regulatory requirements 
in many countries. Indeed, cross-continent planning and collaboration will be 
required to understand similarities and differences as PMS studies become a 
standard practice for multi-national research. Whereas PRO results are useful to 
evaluate patient-relevant effectiveness of the drug, the implementation of a PRO 
survey in PMS in different countries requires careful preparation, such as: 
facilitate multidisciplinary team communications for proper design of a PRO 
survey and selection of a validated survey questionnaire for all participating 
countries; strategize the recruitment of clinicians and patients; develop training 
materials for patient recruitment; handle adverse-event-like symptom questions 
in a questionnaire for adverse drug reaction reporting; develop the report format 
of PRO survey results to regulatory authorities; and develop a communication 
plan of PRO assessment results to stakeholders, such as physicians and patient 
organizations. We will discuss above issues associated with a PRO survey as a 
part of PMS from both Pharmacovigilance and Outcomes Research points of view 
based on our experience in Japan. A comparison will also be made about study 
planning with a PRO component between Japan and global PMS (such as the 
Post-Authorization Surveillance required by the European Medicines Agency), to 
highlight important lessons and implications for PRO researchers and 
practitioners to enhance the usage of PMS as a valuable opportunity to obtain 
real-world PRO assessments.  
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ELECTRONIC PATIENT REPORTED OUTCOMES (EPRO): THE BEST DEFENSE IN 
PREVENTING MISSING PRO DATA  
Ross J, Ross E, Holzbaur E 
Almac Clinical Technologies, Souderton, PA, USA  
This session will illustrate how ePRO is a powerful approach for preventing 
missing data; explain how ePRO is more effective as compared to paper; and 
demonstrate how ePRO techniques can be implemented to prevent missing data. 
ePRO use can be an effective solution for preventing missing data as compared to 
paper data collection. Missing data is common in PROs and can result in 
significant problems for data analysis. While using a robust statistical plan for 
handling missing data is beneficial, studies still can suffer with high levels of 
missing data. One major contributing factor is the collection method. Many PROs 
are still administered in a traditional paper format which can result in high 
levels of missing data. This presentation will illustrate how ePRO can prevent 
missing data through providing examples of various ePRO techniques that can be 
implemented. Primary ePRO techniques to minimize missing data include: hard 
edit check to eliminate patients from skipping items or pages; reminders with 
real time technology to remind patients to complete their PROs; alerts to study 
staff of patient non-compliance; programmed logic to reduce erroneous entries 
and contradicting responses; time stamped data entry to ensure assessments are 
completed within the given window; and storage of directly entered data with 
back-up can ensure data is not lost. ePRO can prevent missing data, improve 
patient compliance and result overall in high quality data. ePRO eliminates many 
of the issues associated with data loss in traditional paper-based PRO systems. 
Future PRO development efforts should focus on creating more electronic 
versions of PRO instruments. Wider availability of ePRO instruments across 
therapeutic areas would ultimately result in high quality data and reduced 
missing data.  
